A randomised phase II study evaluating the efficacy and safety of subcutaneously administered ustekinumab and guselkumab in patients with active rheumatoid arthritis despite treatment with methotrexate

OBJECTIVE: Interleukin (IL)-12 and IL-23 have been implicated in the pathogenesis of rheumatoid arthritis (RA). The safety and efficacy of ustekinumab, a human monoclonal anti-IL-12/23 p40 antibody, and guselkumab, a human monoclonal anti-IL-23 antibody, were evaluated in adults with active RA despi...

Descripción completa

Detalles Bibliográficos
Autores principales: Smolen, Josef S, Agarwal, Sandeep K, Ilivanova, Elena, Xu, Xie Lillian, Miao, Ye, Zhuang, Yanli, Nnane, Ivo, Radziszewski, Waldemar, Greenspan, Andrew, Beutler, Anna, Baker, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5530337/
https://www.ncbi.nlm.nih.gov/pubmed/28087506
http://dx.doi.org/10.1136/annrheumdis-2016-209831

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5530337/
https://www.ncbi.nlm.nih.gov/pubmed/28087506
http://dx.doi.org/10.1136/annrheumdis-2016-209831

Ejemplares similares